TY - JOUR A1 - Isaias, Ioannis U. A1 - Marzegan, Alberto A1 - Pezzoli, Gianni A1 - Marotta, Giorgio A1 - Canesi, Margherita A1 - Biella, Gabriele E. M. A1 - Volkmann, Jens A1 - Cavallari, Paolo T1 - A role for locus coeruleus in Parkinson tremor JF - Frontiers in Human Neuroscience N2 - We analyzed rest tremor, one of the etiologically most elusive hallmarks of Parkinson disease(PD), in 12 consecutive PD patients during a specific task activating the locus coeruleus (LC) to investigate a putative role of noradrenaline (NA) in tremor generation and suppression. Clinical diagnosis was confirmed in all subjects by reduced dopamine reuptake transporter (DAT) binding values investigated by single photon computed tomography imaging (SPECT) with [\(^{123}\)I] N-\(\omega\)-fluoropropyl-2 \(\beta\)-carbomethoxy-3 \(\beta\)-(4-iodophenyl) tropane (FP-CIT). The intensity of tremor (i.e., the power of Electromyography [EMG] signals), but not its frequency, significantly increased during the task. In six subjects, tremor appeared selectively during the task. In a second part of the study, we retrospectively reviewed SPECT with FP-CIT data and confirmed the lack of correlation between dopaminergic loss and tremor by comparing DAT binding values of 82 PD subjects with bilateral tremor (n = 27), unilateral tremor (n = 22), and no tremor (n = 33). This study suggests a role of the LC in Parkinson tremor. KW - locus coeruleus KW - disease KW - basal ganglia KW - resting tremor KW - functional neuroanatomy KW - dopamine KW - norepinephrine KW - progression KW - binding KW - rat KW - noradrenalin KW - parkinson disease KW - tremor Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-133955 VL - 5 IS - 179 ER - TY - JOUR A1 - Fluri, Felix A1 - Schuhmann, Michael K A1 - Kleinschnitz, Christoph T1 - Animal models of ischemic stroke and their application in clinical research JF - Drug Design, Development and Therapy N2 - This review outlines the most frequently used rodent stroke models and discusses their strengths and shortcomings. Mimicking all aspects of human stroke in one animal model is not feasible because ischemic stroke in humans is a heterogeneous disorder with a complex pathophysiology. The transient or permanent middle cerebral artery occlusion (MCAo) model is one of the models that most closely simulate human ischemic stroke. Furthermore, this model is characterized by reliable and well-reproducible infarcts. Therefore, the MCAo model has been involved in the majority of studies that address pathophysiological processes or neuroprotective agents. Another model uses thromboembolic clots and thus is more convenient for investigating thrombolytic agents and pathophysiological processes after thrombolysis. However, for many reasons, preclinical stroke research has a low translational success rate. One factor might be the choice of stroke model. Whereas the therapeutic responsiveness of permanent focal stroke in humans declines significantly within 3 hours after stroke onset, the therapeutic window in animal models with prompt reperfusion is up to 12 hours, resulting in a much longer action time of the investigated agent. Another major problem of animal stroke models is that studies are mostly conducted in young animals without any comorbidity. These models differ from human stroke, which particularly affects elderly people who have various cerebrovascular risk factors. Choosing the most appropriate stroke model and optimizing the study design of preclinical trials might increase the translational potential of animal stroke models. KW - permanent and transient middle cerebral artery occlusion KW - thromboembolic clot model KW - mouse KW - rat KW - microsphere/macrosphere KW - endothelin-1 KW - photothrombosis KW - thromboembolic stroke Y1 - 2015 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-149157 VL - 9 ER - TY - JOUR A1 - Markenstein, Lisa A1 - Appelt-Menzel, Antje A1 - Metzger, Marco A1 - Wenz, Gerhard T1 - Conjugates of methylated cyclodextrin derivatives and hydroxyethyl starch (HES): Synthesis, cytotoxicity and inclusion of anaesthetic actives JF - Beilstein Journal of Organic Chemistry N2 - The mono-6-deoxy-6-azides of 2,6-di-O-methyl-beta-cyclodextrin (DIMEB) and randomly methylated-beta-cyclodextrin (RAMEB) were conjugated to propargylated hydroxyethyl starch (HES) by Cu+-catalysed [2 + 3] cycloaddition. The resulting water soluble polymers showed lower critical solution temperatures (LCST) at 52.5 degrees C (DIMEB-HES) and 84.5 degrees C (RAMEB-HES), respectively. LCST phase separations could be completely avoided by the introduction of a small amount of carboxylate groups at the HES backbone. The methylated CDs conjugated to the HES backbone exhibited significantly lower cytotoxicities than the corresponding monomeric CD derivatives. Since the binding potentials of these CD conjugates were very high, they are promising candidates for new oral dosage forms of anaesthetic actives. KW - midazolam KW - supermolecular carrier systems KW - beta-cyclodextrin KW - pharmaceutical applications KW - gamma-cyclodextrin KW - anaesthetics KW - complexation KW - cyclodextrin KW - LCST KW - lower critical solution temperature KW - acid dissociation KW - drug KW - rat KW - cycloaddition KW - occupancy KW - polymer KW - sevoflurane KW - solubility KW - starch Y1 - 2014 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-114280 SN - 1860-5397 VL - 10 ER - TY - JOUR A1 - Reinhold, A. K. A1 - Batti, L. A1 - Bilbao, D. A1 - Buness, A. A1 - Rittner, H. L. A1 - Heppenstall, P. A. T1 - Differential Transcriptional Profiling of Damaged and Intact Adjacent Dorsal Root Ganglia Neurons in Neuropathic Pain JF - PLoS ONE N2 - Neuropathic pain, caused by a lesion in the somatosensory system, is a severely impairing mostly chronic disease. While its underlying molecular mechanisms are not thoroughly understood, neuroimmune interactions as well as changes in the pain pathway such as sensitization of nociceptors have been implicated. It has been shown that not only are different cell types involved in generation and maintenance of neuropathic pain, like neurons, immune and glial cells, but, also, intact adjacent neurons are relevant to the process. Here, we describe an experimental approach to discriminate damaged from intact adjacent neurons in the same dorsal root ganglion (DRG) using differential fluorescent neuronal labelling and fluorescence-activated cell sorting (FACS). Two fluorescent tracers, Fluoroemerald (FE) and 1-dioctadecyl-3,3,3,3-tetramethylindocarbocyanine perchlorate (DiI), were used, whose properties allow us to distinguish between damaged and intact neurons. Subsequent sorting permitted transcriptional analysis of both groups. Results and qPCR validation show a strong regulation in damaged neurons versus contralateral controls as well as a moderate regulation in adjacent neurons. Data for damaged neurons reveal an mRNA expression pattern consistent with established upregulated genes like galanin, which supports our approach. Moreover, novel genes were found strongly regulated such as corticotropinreleasing hormone (CRH), providing novel targets for further research. Differential fluorescent neuronal labelling and sorting allows for a clear distinction between primarily damaged neuropathic neurons and "bystanders," thereby facilitating a more detailed understanding of their respective roles in neuropathic processes in the DRG. KW - peripheral nerve injury KW - sensory neurons KW - rat KW - involvement KW - mechanisms KW - receptors KW - inhibition KW - expression KW - sciatic nerve KW - inflammatory pain Y1 - 2015 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-143290 VL - 10 IS - 4 ER - TY - JOUR A1 - Sendtner, Michael A1 - Arakawa, Yoshihiro A1 - Stöckli, Kurt A. A1 - Kreutzberg, Georg W. A1 - Thoenen, Hans T1 - Effect of ciliary neurotrophic factor (CNTF) on motoneuron survival N2 - We have demonstrated that the extensive degeneration of motoneurons in the rat facial nucleus after transection of the facial nerve in newborn rats can be prevented by local ciliary neurotrophic factor (CNTF) administration. CNTF differs distinctly from known neurotrophic molecules such as NGF, BDNF and NT-3 in both its molecular characteristics (CNTF is a cytosolic rather than a secretory molecule) and its broad spectrum of biological activities. CNTF is expressed selectively by Schwann cells and astrocytes of the peripheral and central nervous system, respectively, but not by target tissues of the great variety of CNTF -responsive neurons. CNTF mRNA is not detectable by Northern blot or PCR analysis during embryonic development and immediately after birth. However, during the second post-natal week, a more than 30-fold increase in CNTF mRNA and pro tein occurs in the sciatic nerve. Since the period of low CNTF levels in peripheral nerves coincides with that of high vulnerability of motoneurons (i.e. axonallesion results in degeneration of motoneuron cell bodies), insufficient availability of CNTF may be the reason for the rate of lesioninduced cell death of early post-natal motoneurons. Highly enriched embryonic chick motoneurons in culture are supported at survival rates higher than 60% by CNTF, even in single cell cultures, indicating that CNTF acts directly on motoneurons. In contrast to CNTF, the members of the neurotrophin gene family (NGF, BDNF and NT-3) do not support the survival of motoneurons in culture. However, aFGF and bFGF show distinct survival activities which are additive to those of CNTF, resulting in the survival of virtually all motoneurons cultured in the presence of CNTF and bFGF. KW - motoneurons KW - ciliary neurotrophic factor KW - CNTF KW - nerve lesion KW - rat KW - chick KW - neurotrophic factor Y1 - 1991 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-33048 ER - TY - THES A1 - Kroker, Katja T1 - Establishment and validation of hippocampal LTP for characterization of memory enhancing drugs as potential treatment of Alzheimer’s disease T1 - Etablierung und Validierung hippocampalen LTPs zur Charakterisierung gedächtnissteigernde Substanzen zur potentiellen Behandlung der Alzheimer’schen Erkrankung N2 - Die Alzheimer’sche Erkrankung ist eine neurodegenerative Erkrankung des Gehirns. Um geeignete Medikamente für die Behandlung der Alzheimer’schen Erkrankung zu finden, werden experimentelle Modellsysteme zur Erforschung von Substanzkandidaten verwendet. Ein solches experimentelles System ist die hippocampale Langzeitpotenzierung (LTP), welche ein anerkanntes in vitro Modell für die Erforschung der zugrundeliegenden zellulären Prozesse der Gedächtnisbildung ist. Die vorliegende Arbeit beschäftigt sich mit der Etablierung und Validierung von LTP in hippocampalen Hirnschnitten der Ratte um gedächtnissteigernde Substanzen zur potentiellen Behandlung der Alzheimer’schen Erkrankung zu charakterisieren. Dazu wurde zunächst ein Messsystem zur parallelen Charakterisierung mehrerer Schnitte aufgebaut, das Messungen bis zu sieben Stunden erlaubt (Kapitel 2). Dann wurden unterschiedliche Protokolle etabliert um Früh- und Spätphasen-LTP zu generieren. Dabei würde Frühphasen-LTP konzeptionell eher mit dem Kurzzeitgedächtnis einhergehen, während Spätphasen-LTP dem Langzeitgedächtnis gleichkommen würde (Kapitel 3). Da in Alzheimer-Patienten hauptsächlich ein Defizit cholinerger und glutamaterger Neurone vorliegt, wurden die validierten LTP Formen benutzt, um solche Substanzen zu analysieren, die potentiell cholinerge und/oder glutamaterge neuronale Funktion erhöhen. Die Effekte zweier ausschließlich cholinerge Funktion erhöhender Substanzen wurden analysiert: Der α4β2 nicotinische Acetylcholin-Rezeptor Agonist TC-1827 (Kapitel 4) und der Acetylcholinesterase-Inhibitor Donepezil (Kapitel 5). Beide Substanzen erhöhten Frühphasen-LTP, aber hatten keinen Effekt auf Spätphasen-LTP. Desweiteren wurden zwei Substanzen getestet, die ausschließlich mit glutamaterger Funktion interferieren: Der metabotrope Glutamatrezeptor 5 positiv allosterische Modulator ADX-47273 (Kapitel 3) und der Phosphodiesterase (PDE) 9A-Inhibitor BAY 73-6691 (Kapitel 5). ADX-47273 erhöhte Spätphasen-LTP, aber hatte keinen Effekt auf Frühphasen-LTP, wohingegen BAY 73-6691 eine erhöhende Wirkung auf beide LTP Formen aufwies und sogar Früh- in Spätphasen-LTP umwandelte. Die gleichen Effekte, wie bei dem PDE9A-Inhibitor, konnten auch mit dem partiellen α7 nicotinische Acetylcholin-Rezeptor Agonisten SSR180711 (Kapitel 4) demonstriert werden. SSR180711 wirkt sowohl auf cholinerge, als auch auf glutamaterge neuronale Funktion. Dann wurde die Fähigkeit der Substanzen überprüft, durch lösliche Aβ Oligomere verschlechtertes LTP zu verbessern (Kapitel 6). Lösliche Aβ Oligomere, auch als amyloid-β derived diffusible ligands (ADDLs) bezeichnet, werden zurzeit als eine mutmaßliche Ursache der Alzheimer’schen Erkrankung angesehen. In der vorliegenden Arbeit wurde gezeigt, dass ADDLs Früh- und Spätphasen-LTP in verschiedenem Ausmaß vermindern. Donepezil und TC-1827 konnten die durch ADDLs induzierten Defizite bei Frühphasen-LTP geringfügig wiederherstellen, aber sie hatten keinen Einfluss auf das durch ADDLs verschlechterte Spätphasen-LTP. Im Gegensatz dazu, konnten sowohl SSR180711 als auch BAY 73-6691 ein durch ADDLs verschlechtertes Früh- und Spätphasen-LTP komplett wiederherstellen. ADX-47273 hatte keinen positiven Effekt auf Frühphasen-LTP, welches durch ADDLs verschlechtert worden war, konnte aber ein durch ADDLs verschlechtertes Spätphasen-LTP teilweise wiederherstellen. Somit wurde der vorherige Befund der Arbeit bestätigt: Substanzen, welche die glutamaterge Funktion verbessern, scheinen nicht nur wirksamer im Bezug auf LTP-Erhöhung zu sein als Substanzen die ausschließlich cholinerge Funktion erhöhen, sondern sie sind auch in der Lage, durch lösliche Aβ Oligomere verursachte Defizite bei LTP zu verbessern. Aus einem präklinischen Blickwinkel und basierend auf den Ergebnissen der vorliegenden Arbeit weisen demnach Substanzen, die glutamaterge Funktionen verbessern, ein hohes therapeutisches Potential als alternative Ansätze bezüglich kognitiver Defizite auf. Möglicherweise könnten sie sogar wirksamere Ansätze für die symptomatische Behandlung der Alzheimer’schen Erkrankung darstellen, als derzeitige Behandlungen, die ausschließlich cholinerge Funktion verbessern. N2 - Alzheimer’s disease (AD) is a progressive neurodegenerative disease of the brain. Today AD is the most common form of dementia in elderly people. It is clinically characterized by a progressive loss of memory and later on a decline in higher cognitive functions. The pathological hallmarks of AD, consistently demonstrated in brain tissue of patients, are extracellular amyloid-β (Aβ plaques, intracellular neurofibrillary tangles of tau protein and a profound loss of mainly cholinergic and glutamatergic synapses and ultimatively neurons. Estimates foresee that more than 80 million individuals will be affected by the disease by 2040 due to population aging worldwide underlining the high medical need for this disease. In order to find suitable drugs for the treatment of AD, experimental model systems are utilized to explore potential drug candidates. Such an experimental system is hippocampal long-term potentiation (LTP), which is widely accepted as an in vitro model of cellular processes fundamentally involved in memory formation. The present thesis focuses on the establishment and validation of LTP in rat hippocampal slices to characterize memory enhancing drugs as a potential treatment of AD. First, a multi-slice recording system was set up enabling stable measurements of LTP for up to seven hours from several slices simultaneously (chapter 2). Then, distinct protocols to induce early and late CA1 LTP, resembling short-term and long-term memory, were established. They were validated by addressing the hallmarks accepted for these forms of LTP: protein-synthesis independence and NMDA receptor dependence without contribution of L-VDCCs for early LTP, as opposed to protein-synthesis and NMDA / L-VDCCs dependence for late LTP (chapter 3). As in AD patients a loss of mainly cholinergic and glutamatergic synapses is obvious, these validated forms of LTP were used to study drugs potentially being able to enhance cholinergic and/or glutamatergic neuronal functions. The effects of two drugs exclusively interfering with cholinergic function on LTP were tested: the α4β2 nicotinic acetylcholinergic receptor agonist TC-1827 (chapter 4) and the acetylcholine esterase inhibitor donepezil (chapter 5). Both drugs were found to increase early LTP, but to not affect late LTP. Furthermore, two drugs exclusively interfering with glutamatergic function were analyzed: the metabotropic glutamate 5 receptor postive allosteric modulator ADX-47273 (chapter 3) and the phosphodiesterase (PDE) 9A inhibitor BAY 73-6691 (chapter 5). ADX-47273 increased late LTP, but had no effect on early LTP, whereas BAY 73-6691 showed enhancing effects on both early and late LTP and even transformed early into late LTP. The same effects like for the PDE9A inhibitor were observed for the α7 nicotinic acetylcholinergic receptor partial agonist SSR180711 (chapter 4), which interferes with both, cholinergic and glutamatergic function. Thus, drugs facilitating glutamatergic function or both glutamatergic and cholinergic function seem to be more efficacious in enhancing LTP than drugs facilitating solely cholinergic function. To evaluate whether this finding also proves true for experimental circumstances mimicking decreased cognitive function together with pathophysiology in AD patients, the ability of the drugs to ameliorate LTP impaired by soluble Aβ oligomer was analyzed (chapter 6). Soluble Aβ oligomers, also referred to as amyloid-β derived diffusible ligands (ADDLs), are thought to a putative cause of AD. Here, they were demonstrated to impair early and late LTP to different extents by exclusively targeting NMDA receptors and/or their signaling. These results further contribute to the hypothesis that soluble Aβ oligomers cause synaptic dysfunction which might lead to cognitive decline seen in AD patients. Regarding drug effects, donepezil and TC-1827 slightly restored ADDLs induced impairment of early LTP, but had no effect on late LTP impaired by ADDLs. In contrast, both, SSR180711 and BAY 73-6691 completely rescued early as well as late LTP impaired by ADDLs. ADX-47273 had no restoring effect on ADDLs induced early LTP impairment, but partially restored late LTP impaired by ADDLs. Thus, the earlier finding of the present thesis was confirmed: drugs facilitating glutamatergic function not only seem to be more efficacious in enhancing LTP than drugs facilitating solely cholinergic function, but are also superior in ameliorating soluble Aβ oligomer induced LTP deficits. Therefore, from a preclinical perspective and based on the results of the present thesis, drugs interfering with glutamatergic function seem to have a high therapeutic potential as alternative treatment concerning cognitive deficits. Probably, they represent more efficacious approaches for the symptomatic treatment of AD than current treatments solely facilitating cholinergic function. KW - Alzheimerkrankheit KW - Long-term potentiation KW - hippocampus KW - rat KW - learning and memory KW - Langzeitpotenzierung KW - Hippocampus KW - Ratte KW - Wirkstoff Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-85412 ER - TY - JOUR A1 - Cox-Limpens, Kimberly E. M. A1 - Vles, Johan S. H. A1 - van den Hove, Daniel L. A. A1 - Zimmermann, Luc Ji A1 - Gavilanes, Antonio W. D. T1 - Fetal asphyctic preconditioning alters the transcriptional response to perinatal asphyxia JF - BMC Neuroscience N2 - Background: Genomic reprogramming is thought to be, at least in part, responsible for the protective effect of brain preconditioning. Unraveling mechanisms of this endogenous neuroprotection, activated by preconditioning, is an important step towards new clinical strategies for treating asphyctic neonates. Therefore, we investigated whole-genome transcriptional changes in the brain of rats which underwent perinatal asphyxia (PA), and rats where PA was preceded by fetal asphyctic preconditioning (FAPA). Offspring were sacrificed 6 h and 96 h after birth, and whole-genome transcription was investigated using the Affymetrix Gene1.0ST chip. Microarray data were analyzed with the Bioconductor Limma package. In addition to univariate analysis, we performed Gene Set Enrichment Analysis (GSEA) in order to derive results with maximum biological relevance. Results: We observed minimal, 25% or less, overlap of differentially regulated transcripts across different experimental groups which leads us to conclude that the transcriptional phenotype of these groups is largely unique. In both the PA and FAPA group we observe an upregulation of transcripts involved in cellular stress. Contrastingly, transcripts with a function in the cell nucleus were mostly downregulated in PA animals, while we see considerable upregulation in the FAPA group. Furthermore, we observed that histone deacetylases (HDACs) are exclusively regulated in FAPA animals. Conclusions: This study is the first to investigate whole-genome transcription in the neonatal brain after PA alone, and after perinatal asphyxia preceded by preconditioning (FAPA). We describe several genes/pathways, such as ubiquitination and proteolysis, which were not previously linked to preconditioning-induced neuroprotection. Furthermore, we observed that the majority of upregulated genes in preconditioned animals have a function in the cell nucleus, including several epigenetic players such as HDACs, which suggests that epigenetic mechanisms are likely to play a role in preconditioning-induced neuroprotection. KW - Perinatal Asphyxia KW - oxidative stress KW - microarray KW - cerebral artery occlusion KW - ischemic brain injury KW - genomic response KW - protein aggregation KW - immediate early genes KW - neuroprotection KW - tolerance KW - rat KW - expression KW - transient global ischemia KW - ubiquitination KW - epigenetics KW - fetal preconditioning KW - neonatal brain Y1 - 2014 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-116185 VL - 15 ER - TY - THES A1 - Lin, Chia-Huey T1 - Functional characterization of rat CTLA-4 and CD25+CD4+ regulatory T cells T1 - Funktionelle Chracterisierung der Ratte CTLA-4 und CD25+CD4+ regulatorischen T Zellen N2 - Summary: In the present work, two important negative regulators of T cell responses in rats were examined. At the molecular level, rat CTLA-4, a receptor important for deactivating T cell responses, was examined for the expression pattern and in vitro functions. For this purpose, anti-rat CTLA-4 mAbs were generated. Consistent with the studies in mice and humans, rat CTLA-4 was detectable only in CD25+CD4+ regulatory T cells in unstimulated rats, and was upregulated in all activated T cells. Cross-linking rat CTLA-4 led to the deactivation of anti-TCR- and anti-CD28 stimulated (costimulation) T cell responses such as reduction in activation marker expression, proliferation, and cytokine IL-2 production. Although T cells stimulated with the superagonistic anti-CD28 antibody alone without TCR engagement also increased their CTLA-4 expression, a delayed kinetics of CTLA-4 upregulation was found in cells stimulated in this way. The physiological relevance of this finding needs further investigation. At the cellular level, rat CD25+CD4+ regulatory T cells were examined here in detail. Using rat anti-CTLA-4 mAbs, the phenotype of CD25+CD4+ regulatory T cells was investigated. Identical to the mouse and human Treg phenotype, rat CD25+CD4+ T cells constitutively expressed CTLA-4, were predominantly CD45RC low, and expressed high level of CD62L (L-selectin). CD25+CD4+ cells proliferated poorly and were unable to produce IL-2 upon engagement of the TCR and CD28. Furthermore, rat CD25+CD4+ cells produced high amounts of anti-inflammatory cytokine IL-10 upon stimulation. Importantly, freshly isolated CD25+CD4+ T cells from naïve rats exhibited suppressor activities in the in vitro suppressor assays. In vitro, CD25+CD4+ regulatory T cells proliferated vigorously upon superagonistic anti-CD28 stimulation and became very potent suppressor cells. In vivo, a single injection of CD28 superagonist into rats induced transient accumulation and activation of CD25+CD4+ regulatory T cells. These findings suggest firstly that efficient expansion of CD25+CD4+ cells without losing their suppressive effects (even enhance their suppressive activities) can be achieved with the superagonistic anti- CD28 antibody in vitro. Secondly, the induction of disproportional expansion of CD25+CD4+ cells by a single injection of superagonistic anti-CD28 antibody in vivo implies that superagonistic anti-CD28 antibody may be a promising candidate in treating autoimmune diseases by causing a transient increase of activated CD25+CD4+ T cells and thus tipping ongoing autoimmune responses toward selftolerance. N2 - Zusammenfassung: In der vorliegenden Arbeit wurden zwei wichtige negative Regulatoren von T Zellantworten in der Ratte untersucht. Auf molekularer Ebene wurde Ratten-CTLA-4, ein für die Deaktivierung von T-Zellimmunantworten wichtiger Rezeptor, hinsichtlich seines Expressionsmusters und seiner in vitro Funktionen untersucht. Zu diesem Zweck wurden spezifische monoklonale Antikörper gegen Ratten-CTLA-4 erzeugt. In Übereinstimmung mit anderen Untersuchungen in Mensch und Maus war CTLA-4 konstitutiv nur in CD25+CD4+ regulatorischen T-Zellen exprimiert, nach Stimulierung war es in allen aktivierten T-Zellen nachweisbar. Kreuzvernetzung von CTLA-4 führte zur Inhibition von mit anti-TCR- und anti-CD28-Antikörpern stimulierten (Kostimulation) TZellantworten, insbesondere zur Verminderung der Expression von Aktivierungsmarkern, der Proliferation und der Produktion von IL-2. Obwohl T-Zellen mit superagonistischem Anti-CD28-Antikörper ohne T-Zellrezeptor stimulation ihre CTLA-4-Expression ebenfalls steigerten, wurde eine verzögerte Kinetik für die Hochregulation von CTLA-4 in diesen Zellen festgestellt. Die physiologische Bedeutung dieses Befundes bedarf noch weiterer Untersuchungen. Auf zellulärer Ebene wurden CD25+CD4+ regulatorische T-Zellen detailliert analysiert. Der Phänotyp CD25+CD4+ regulatorischen T-Zellen wurde charakterisiert. Wie in Mensch und Maus exprimierten die regulatorischen T-Zellen der Ratte konstitutiv CTLA-4, in größerem Umfang CD62L (L-Selectin), aber nur wenig CD45RC. CD25+CD4+ Zellen proliferierten nach Stimulation von CD28 und T-Zellrezeptor nur schwach und produzierten kein IL-2, im Gegensatz dazu aber große Mengen an IL-10. Hervorzuheben ist, dass für frisch isolierte CD25+CD4+ T-Zellen aus naiven Ratten Suppressoraktivität durch in vitro-Suppressionsassays nachgewiesen werden konnte. In vitro proliferierten CD25+CD4+ regulatorische T-Zellen nach superagonistischer anti-CD28-Stimulation äußerst stark und wurden zu potenten Suppressorzellen. Eine einzelne Injektion von superagonistischem Anti-CD28-Antikörper resultierte in einer transienten Akkumulation von CD25+CD4+ regulatorischen T-Zellen in vivo und induzierte deren Aktivierung. Diese Ergebnisse weisen zum einen darauf hin, dass eine effiziente Expansion von CD25+CD4+ Zellen ohne Verlust ihrer supprimierenden Effekte durch superagonistischen Anti-CD28-Antikörper in vitro erzielt werden kann. Zum anderen läßt die Induktion einer disproportionalen Expansion von CD25+CD4+ Zellen durch eine einzige Injektion des CD28-Superagonisten den Schluss zu, dass dieser Antikörper ein vielversprechender Kandidat zur Behandlung von Autoimmunkrankheiten sein könnte, der über eine transiente Zunahme von aktivierten CD25+CD4+ T-Zellen eine bestehende Autoimmunantwort hin zur Selbsttoleranz lenkt. KW - Ratte KW - T-Lymphozyt KW - Desaktivierung KW - CTLA-4 KW - Regulatorische T Zellen KW - CD28 superagonist KW - Ratte KW - Toleranz KW - CTLA-4 KW - CD25+CD4+ regulatory T cells KW - CD28 superagonist KW - rat KW - peripheral tolerance Y1 - 2004 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-8521 ER - TY - JOUR A1 - Hetz, Susan A1 - Acikgoez, Ali A1 - Voss, Ulrike A1 - Nieber, Karen A1 - Holland, Heidrun A1 - Hegewald, Cindy A1 - Till, Holger A1 - Metzger, Roman A1 - Metzger, Marco T1 - In Vivo Transplantation of Neurosphere-Like Bodies Derived from the Human Postnatal and Adult Enteric Nervous System: A Pilot Study JF - PLOS ONE N2 - Recent advances in the in vitro characterization of human adult enteric neural progenitor cells have opened new possibilities for cell-based therapies in gastrointestinal motility disorders. However, whether these cells are able to integrate within an in vivo gut environment is still unclear. In this study, we transplanted neural progenitor-containing neurosphere-like bodies (NLBs) in a mouse model of hypoganglionosis and analyzed cellular integration of NLB-derived cell types and functional improvement. NLBs were propagated from postnatal and adult human gut tissues. Cells were characterized by immunohistochemistry, quantitative PCR and subtelomere fluorescence in situ hybridization (FISH). For in vivo evaluation, the plexus of murine colon was damaged by the application of cationic surfactant benzalkonium chloride which was followed by the transplantation of NLBs in a fibrin matrix. After 4 weeks, grafted human cells were visualized by combined in situ hybridization (Alu) and immunohistochemistry (PGP9.5, GFAP, SMA). In addition, we determined nitric oxide synthase (NOS)-positive neurons and measured hypertrophic effects in the ENS and musculature. Contractility of treated guts was assessed in organ bath after electrical field stimulation. NLBs could be reproducibly generated without any signs of chromosomal alterations using subtelomere FISH. NLB-derived cells integrated within the host tissue and showed expected differentiated phenotypes i.e. enteric neurons, glia and smooth muscle-like cells following in vivo transplantation. Our data suggest biological effects of the transplanted NLB cells on tissue contractility, although robust statistical results could not be obtained due to the small sample size. Further, it is unclear, which of the NLB cell types including neural progenitors have direct restoring effects or, alternatively may act via 'bystander' mechanisms in vivo. Our findings provide further evidence that NLB transplantation can be considered as feasible tool to improve ENS function in a variety of gastrointestinal disorders. KW - Hirschsprung disease KW - benzalkonium chloride KW - progenitors KW - GUT KW - rat KW - colon KW - biology KW - therapy KW - neural stem-cell KW - motility disorders Y1 - 2014 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-116793 VL - 9 IS - 4 ER - TY - JOUR A1 - Schaeffer, Evelin L. A1 - Kühn, Franziska A1 - Schmitt, Angelika A1 - Gattaz, Wagner F. A1 - Gruber, Oliver A1 - Schneider-Axmann, Thomas A1 - Falkai, Peter A1 - Schmitt, Andrea T1 - Increased cell proliferation in the rat anterior cingulate cortex following neonatal hypoxia: relevance to schizophrenia JF - Journal of Neural Transmission N2 - As a consequence of obstetric complications, neonatal hypoxia has been discussed as an environmental factor in the pathophysiology of schizophrenia. However, the biological consequences of hypoxia are unclear. The neurodevelopmental hypothesis of schizophrenia suggests that the onset of abnormal brain development and neuropathology occurs perinatally, whereas symptoms of the disease appear in early adulthood. In our animal model of chronic neonatal hypoxia, we have detected behavioral alterations resembling those known from schizophrenia. Disturbances in cell proliferation possibly contribute to the pathophysiology of this disease. In the present study, we used postnatal rats to investigate cell proliferation in several brain areas following neonatal hypoxia. Rats were repeatedly exposed to hypoxia (89 % N2, 11 % O2) from postnatal day (PD) 4–8. We then evaluated cell proliferation on PD 13 and 39, respectively. These investigations were performed in the anterior cingulate cortex (ACC), caudate-putamen (CPU), dentate gyrus, and subventricular zone. Rats exposed to hypoxia exhibited increased cell proliferation in the ACC at PD 13, normalizing at PD 39. In other brain regions, no alterations have been detected. Additionally, hypoxia-treated rats showed decreased CPU volume at PD 13. The results of the present study on the one hand support the assumption of chronic hypoxia influencing transient cell proliferation in the ACC, and on the other hand reveal normalization during ageing. KW - schizophrenia KW - cell proliferation KW - rat KW - anterior cingulate cortex KW - neonatal hypoxia Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-125890 VL - 120 IS - 1 ER -